化学
基诺美
激酶
催化亚单位
DNA损伤
选择性
奥拉帕尼
生物化学
P110α
DNA
蛋白质亚单位
基因
聚ADP核糖聚合酶
聚合酶
催化作用
作者
Frederick W. Goldberg,M. Raymond V. Finlay,Attilla Ting,David T. Beattie,Gillian M. Lamont,Charlene Fallan,Gail L. Wrigley,Marianne Schimpl,Martin Howard,Beth Williamson,Mercedes Vázquez–Chantada,Derek Barratt,Barry R. Davies,Elaine Cadogan,Antonio Ramos‐Montoya,Emma Dean
标识
DOI:10.1021/acs.jmedchem.9b01684
摘要
DNA-PK is a key component within the DNA damage response, as it is responsible for recognizing and repairing double-strand DNA breaks (DSBs) via non-homologous end joining. Historically it has been challenging to identify inhibitors of the DNA-PK catalytic subunit (DNA-PKcs) with good selectivity versus the structurally related PI3 (lipid) and PI3K-related protein kinases. We screened our corporate collection for DNA-PKcs inhibitors with good PI3 kinase selectivity, identifying compound 1. Optimization focused on further improving selectivity while improving physical and pharmacokinetic properties, notably co-optimization of permeability and metabolic stability, to identify compound 16 (AZD7648). Compound 16 had no significant off-target activity in the protein kinome and only weak activity versus PI3Kα/γ lipid kinases. Monotherapy activity in murine xenograft models was observed, and regressions were observed when combined with inducers of DSBs (doxorubicin or irradiation) or PARP inhibition (olaparib). These data support progression into clinical studies (NCT03907969).
科研通智能强力驱动
Strongly Powered by AbleSci AI